Point72 Asia (Singapore) Pte. Ltd. Ventyx Biosciences, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 12,096 shares of VTYX stock, worth $28,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,096
Previous 25,303
52.2%
Holding current value
$28,425
Previous $58.5 Million
54.89%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VTYX
# of Institutions
125Shares Held
52.9MCall Options Held
35.3KPut Options Held
83K-
Deerfield Management Company, L.P. (Series C) New York, NY6.72MShares$15.8 Million0.27% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$11.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$8.15 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.45 Million0.03% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $133M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...